



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH

# Maps from the EMIS-2017 Report

Citation: The EMIS Network.  
EMIS-2017: The European Men-Who-Have-Sex-With-Men Internet Survey

Authors: Peter Weatherburn, Ford Hickson, David S. Reid,  
Susanne B. Schink, Ulrich Marcus, Axel J. Schmidt

Primary Funding: EU Health Programme 2014-2020

Contact: [coordinator@emis-project.eu](mailto:coordinator@emis-project.eu)



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH

# Response & Demographics

**Figure 2.2**

**Number of respondents and crude recruitment rate per country**  
N=127 792 for Europe




ROBERT KOCH INSTITUT





**Sigma**  
RESEARCH

Number of respondents



Crude recruitment rate





ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH

# Morbidities

**Figure 4.1**

**Percentage with severe anxiety or depression in last two weeks (PHQ-4)**


N=125 856



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH



**Figure 4.3**

**Percentage with potential alcohol dependency (CAGE4)**


N=126 146



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH



**Figure 4.4**


**Percentage ever diagnosed with HIV (DDM 4.79, GAM 4.20)**  
N=126 925



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH



**Figure 4.5**


**Percentage diagnosed with HIV, last 12 months**  
N=115 002



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH







ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH

# Behaviour

**Figure 5.1**


**Percentage currently taking PrEP, excluding HIV-diagnosed men (DDM 3.29)**  
N=112 939



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH




**Figure 5.5**  
**Percentage who had condomless anal intercourse**  
**with non-steady partners of unknown HIV status, last 12 months (DDM 3.27)**  
N=126 493



ROBERT KOCH INSTITUT





**Sigma**  
RESEARCH



**Figure 5.12**  
**Percentage who used stimulant drugs\* to make sex more intense or last longer ('chemsex'), last four weeks (DDM 2.50)**

N=126 258

\*including ecstasy/MDMA, cocaine, amphetamine (speed), crystal meth-amphetamine (Tina, Pervitin), mephedrone, and ketamine





ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH

# Needs



### Figure 6.3


## Percentage lacking social support, scoring <10 on either Reliable Alliance or Social Integration sub-scales of the Social Provisions Scale

N=57 853 (random 50% of respondents)

ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH



**Figure 6.5**



**Score (mean) for the Short Internalised Homonegativity Scale (range, 0 to 6)**



N=55 301 (random 50% of respondents)

ROBERT KOCH INSTITUT





**Sigma**  
RESEARCH

Higher scores indicate a higher level of internalised homonegativity as a consequence of homonegative social climates.



**Figure 6.6**  
**Percentage PrEP knowledge\***  
N=127 051



\* Already knew:  
"Pre-Exposure prophylaxis (PrEP) involves someone who does not have HIV taking pills before as well as after sex to prevent them getting HIV."





**Figure 6.7**  
**Percentage U=U knowledge\***  
N=127 425

\* Already knew:  
"A person with HIV who is on effective treatment (called 'undetectable viral load') cannot pass their virus to someone else during sex."



**Figure 7.3**

**Percentage who saw or heard information about HIV or STIs for MSM,  
last 12 months (DDM 3.5a)**


N=107 498



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH





# Interventions

**Figure 7.4**

**Percentage tested for HIV, last 12 months, excluding men diagnosed prior to this (DDM 4.53)**


N=127 487



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH



**Figure 7.5**

**Percentage using community HIV-testing at last HIV test (DDM 4.13a)**


N=115 869



ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH




**Figure 7.8**  
**Percentage with full course of hepatitis A vaccination, excluding men with a history of hepatitis A (DDM 3.10a)**  
N=117 748




ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH



Coverage ranges as recommended by ECDC, "high coverage" defined as up to 95%.



**Figure 7.9**  
**Percentage with full course of hepatitis B vaccination, excluding men with a history of hepatitis B (DDM 3.10b)**  
N=119 277




ROBERT KOCH INSTITUT



**Sigma**  
RESEARCH


- Low Coverage (<30%)
- Medium Coverage (30-60%)
- High Coverage (61-73%)

Coverage ranges as recommended by ECDC, "high coverage" defined as up to 95%.



**Figure 7.11**  
**Percentage with full STI screen**  
**(HIV, STI blood test, rectal swab, urethral swab or urine), last 12 months**  
N=115 869

As recommended for PrEP monitoring, excluding those diagnosed with HIV longer than 12 months ago.







**EMIS-2017** was undertaken by Sigma Research at London School of Hygiene and Tropical Medicine (LSHTM) in association with Robert Koch Institute (RKI) in Berlin.

**Other international financial contributions:** Swedish Ministry of Health for recruitment in the Nordic Countries;

The Arctic University of Norway and University Hospital of North Norway for Russia; Israel Ministry of Health for Israel;

Public Health Agency of Canada for Canada; Office of the WHO Representative in the Philippines for the Philippines..

**Acknowledgements:** We begin by thanking all of the men who took part in EMIS-2017 and our partners who recruited 17% of all respondents through activities on Facebook and other social media and by placing EMIS banners on their websites. **We thank all our partners for being part of something huge!**

We thank Teymur Noori for great help ECDC's EMMa mapping software.

**Contributors: Pan-European:** PlanetRomeo, European AIDS Treatment Group (EATG), Eurasian Coalition on Male Health (ECOM), European Centre for Disease Prevention and Control (ECDC), European Monitoring Centre for Drugs & Drug Addiction (EMCDDA), European Commission (DG SANTE).

**AL:** Arian Boci. **AT:** Aids Hilfe Wien, Dr Frank M. Amort. **BA:** Igbti.ba, Masha Durkalić. **BE:** SENSOA, exaequo, Observatoire du SIDA et des sexualités. **BG:** HUGE, GLAS Foundation, Dr. Emilia Naseva, Petar Tsintsarski. **BY:** Vstrecha. **CA:** Health Initiative for Men, Rézo, Gay Men's Sexual Health Alliance of Ontario, CATIE, Université du Québec & Montréal, University of Toronto, Ryerson University, University of Windsor, University of Victoria, Public Health Agency of Canada, Rob Gair. **CH:** Swiss AIDS Federation, Cantonal Hospital St. Gallen, Centre Hospitalier Universitaire Vaudois, University Hospital Zurich, Swiss Federal Office of Public Health. **CY:** AIDS Solidarity Movement. **CZ:** AIDS pomoc, National Institute of Public Health, Tereza Zvolaska, Dr Michał Pitonak. **DE:** Deutsche AIDS-Hilfe, Robert Koch Institute, BZgA, Dr Michael Bochow, Dr Richard Lemke. **DK:** AIDS-Fondet, Statens Serum Institut, François Pinchon, Jakob Haff. **EE:** Eesti LGBT, VEK LGBT, Estonia National Institute for Health Development, Dr Kristi Rüütel. **ES:** Stop Sida, CEEISCAT, Ministerio de Sanidad. **FI:** Positiiviset, Hivpoint, SeksiPertti, Trasek. **FR:** AIDES, Coalition PLUS, SexoSafe, Santé Publique France, INSERM. **GR:** Ath Checkpoint, Thess Checkpoint; Positive Voice. **HR:** Iskorak, gay.hr, Zoran Dominković, Vjeko Vacek. **HU:** Háttér, Tamás Bereczky. **IE:** Gay Health Network, Man2Man, HIV Ireland, Outhouse, GOSHH, Sexual Health Centre Cork, AIDSWEST, Gay Community News, Health Service Executive, Gay Men's Health Service, Sexual Health and Crisis Pregnancy Programme, Health Protection Surveillance Centre, Mick Quinlan. **IL:** Israel AIDS Task Force, Israel Ministry of Health, Dr Zohar Mor. **IS:** Samtökin'78. **IT:** Arcigay, Fondazione LILA Milano ONLUS, University of Verona, Dr Raffaele Lelleri. **LB:** SIDC, Dr Ismaël Maatouk. **LT:** demetra, LGL, Gayline. **LV:** Testpunkts, Baltic HIV Association, Dr Antons Mozalevskis, Indra Linina. **MD:** GENDERDOC-M. **ME:** Juventas. **MK:** Subversive Front, Kristefer Stojanovski. **MT:** Malta LGBTIQ Rights Movement, Allied Rainbow Communities, Infectious Disease Prevention and Control Unit (Malta), Silvan Agius, Russel Sammut. **NL:** Results in Health, Maastricht University, Amsterdam Pink Panel, Soa Aids Nederland, Rutgers, Dr Wim Vanden Berghe. **NO:** Helseutvalget, Folkehelseinstituttet, Dr Rigmor C. Berg. **PH:** Bisdak Pride-Cebu, Cebu Plus, HASH, Pinoy Plus, UP Babaylanes, YPEER, TLF, Natasha Montevirgen, Mikael N. Navarro. **PL:** Spoleczny Komitet ds AIDS, Kampania Przeciw Homofobii, Lambda Warszawa, Dr Łukasz Henszel. **PT:** GAT Portugal, CheckpointLX, Associação ABRAÇO, rede ex aequo, SexED, dezanove, ILGA Portugal, Trombeta Bath, ISPUP. **RO:** Association "Eu sunt! Tu?", PSI Romania, ARAS Romania, Tudor Kovacs. **RS:** Association Duga, Association Red Line, Omladina JAZAS-a Novi Sad, Institute of Public Health of Serbia, Sladjana Baros, Dr Marija Pantelic. **RU:** LaSky. **SE:** RFSL, University of Gothenburg, Folkhälsomyndigheten. **SI:** ŠKUC, Legebitra, LJUDMILA. **SK:** PRIDE Košice, Light-House Slovakia, Slovak Medical University, Public Health Authority of the Slovak Republic, Dr Zuzana Klocháňová. **TR:** Pozitif Yaşam, Sami Sarper Yazıcılaroğlu. **UA:** Alliance for Public Health, alliance.global, msmua.org, Oleksii Shestakovskiyi. **UK:** Terrence Higgins Trust, NAM, PrEPster, Antidote, Horizon Drugs and Alcohol Support, LGBT Foundation, Yorkshire MESMAC, MESMAC Newcastle, Derbyshire LGBT+, Trade Sexual Health, London Friend, GMFA, Spectra, International HIV Partnerships, International Planned Parenthood Federation, Bristol University, University College London, Sigma Research, Raul Soriano. **Other:** Dr John Pachankis, Dr Mark Hatzenbühler, Dr Valeria Stuardo Ávila, Dr Michael W. Ross.